Skip to main content

Table 1 Human cervical tissue as a drug reservoir for protection of T cells

From: Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties

Drug

JT-CCR5 Infection

 

Co-culture JT-CCR5 &explant tissue

 
 

IC50(μM)

IC90(μM)

IC50(μM)

IC90(μM)

TDF

0.04 ± 0.01

0.13 ± 0.02

>10.0

>10.0

IQP-0528

0.19 ± 0.07

0.43 ± 0.16

2.9 ± 0.7

10.1 ± 0.7

DPV

0.01 ± 0.01

0.03 ± 0.02

0.4 ± 0.2

1.1 ± 0.3

MVC

1.98 ± 0.85

54.5 ± 13.8

>100

>100

Chol-PIE12 trimer

<0.0001

0.009 ± 0.007

0.008 ± 0.004

0.09 ± 0.01

TDF + IQP-0528

0.01 ± 0.01

0.03 ± 0.02

0.5 ± 0.2

9.5 ± 0.8

  1. JT-CCR5 cells were challenged with HIV-1Ba-L in the presence of indicated drugs. Alternatively, human ectocervical explants were exposed to the same panel of drugs for 24 h, washed, and then co-cultured with JT-CCR5 cells prior to challenge with virus. IC50 and IC90 values were calculated from at least two experiments with each condition tested in triplicate and are means ± SEM.